Non-antibiotic properties of tetracyclines and their clinical application in dermatology

Australasian Journal of Dermatology

Volumn 55, Issue 2, 2014, Pages 111-118

  Perret, Leanna J ^a   Tait, Clare P ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

anti inflammatory; dermatology; doxycycline minocycline; matrix metalloproteinase; non antibiotic; tetracycline

Indexed keywords

CHLORTETRACYCLINE; DOXYCYCLINE; GAMMA INTERFERON; GLYCYLCYCLINE DERIVATIVE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; METRONIDAZOLE; MINOCYCLINE; OXYTETRACYCLINE; REACTIVE OXYGEN METABOLITE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; MATRIX METALLOPROTEINASE INHIBITOR;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANTICOLLAGENASE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE SKIN DISEASE; BONE METABOLISM; CALCIUM CELL LEVEL; CELL MOTION; CONFLUENT AND RETICULATED PAPILLOMATOSIS; CONNECTIVE TISSUE CELL; DERMATOLOGY; DRUG ABSORPTION; DRUG ACTIVITY; EXTRACELLULAR MATRIX; FOLLICULITIS; GRANULOMA; GRANULOMATOSIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; KAPOSI SARCOMA; LEUKOCYTE MIGRATION; LIPID PEROXIDATION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; PATHOPHYSIOLOGY; PITYRIASIS LICHENOIDES; PROPIONIBACTERIUM ACNES; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; SUPPURATIVE HIDRADENITIS; ACNE VULGARIS; PEMPHIGOID, BULLOUS; SKIN DISEASES;

ACNE VULGARIS; ANTI-INFLAMMATORY AGENTS; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; PEMPHIGOID, BULLOUS; ROSACEA; SKIN DISEASES; TETRACYCLINES;

EID: 84899064284     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12075     Document Type: Review

References (61)

1. Duggar BM,. Aureomycin; a product of the continuing search for new antibiotics. Ann. N.Y. Acad. Sci. 1948; 51: 177-181.
2. Jonas M, Comer JB, Cunha BA,. Tetracyclines. In:, Ristuccia AM, Cunha BA, (eds). Antimicrobial Therapy. New York: Raven Press, 1984; 219-234.
3. Nelson ML,. Chemical and biological dynamics of tetracyclines. Adv. Dent. Res. 1998; 12: 5-11.
4. Weinberg J,. The anti-inflammatory effects of tetracyclines. Cutis 2005; 75: 6-11.
5. White JR, Pearce FL,. Characterization of chlortetracycline (aureomycin) as a calcium ionophore. Biochemistry 1982; 21: 6309-6312.
6. Agwuh KN, MacGowan A,. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 2006; 58: 256-265.
7. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res. 1998; 12: 12-26.
8. Nagase H, Woessner JF,. Matrix metalloproteinases. J. Biol. Chem. 1999; 274: 21419-21494.
9. Stetler-Steveson WG, Liotta LA, Kleiner DE,. Extracellular matrix 6: role of matrix metalloproteinases in tumour invasion and metastasis. FASEB J. 1993; 7: 1434-1441.
10. Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J. Periodont. Res. 1983; 18: 516-526.
11. Golub LM, Ramamurthy NS, McNamara TF, et al. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. 1991; 2: 297-321.
12. Griffin MO, Fricovsky E, Ceballos G,. et al. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am. J. Physiol. Cell Physiol. 2010; 299: C539-C548.
13. Bikowski JB,. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003; 2: 234-245.
14. Peterson JT,. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail. Rev. 2004; 9: 63-79.
15. Bahrami F, Morris DL, Pourgholami MH,. Tetracyclines: drugs with huge therapeutic potential. Mini Rev. Med. Chem. 2012; 12: 44-52.
16. Webster G, Del Rosso JQ,. Anti-inflammatory activity of tetracyclines. Dermatol. Clin. 2007; 25: 133-135.
17. Martin RR, Warr GA, Couch RB, et al. Effects of tetracyclines on leukotaxis. J. Infect. Dis. 1974; 129: 110-116.
18. Esterly NB, Furey NL, Flanagan LE,. The effect of antimicrobial agents on leukocyte chemotaxis. J. Invest. Dermatol. 1978; 70: 51-55.
19. Goodheart GL,. Further evidence of the role of bivalent cations in leukocyte chemotaxis. J. Reticuloendothel. Soc. 1979; 25: 545-554.
20. Kloppenburg M, Breedveld FC, Terwiel J, et al. The influence of tetracyclines on T cell activation. Clin. Exp. Immunol. 1995; 102: 635-641.
21. 2. J. Mol. Biol. 2010; 398: 83-96.
22. Monk E, Shalita A, Siegel DM,. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharm. Res. 2011; 63: 130-145.
23. Kraus RL, Pasieczny R, Lariosa-Willingham K, et al. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical scavenging activity. J. Neurochem. 2005; 94: 819-827.
24. Amin AR, Patel RN, Thakker GD, et al. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett. 1997; 410: 259-264.
25. Whiteman M, Halliwell B,. Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha 1-antiprotease by antibiotics. Free Radic. Res. 1997; 26: 49-56.
26. Tomas-Camardiel M, Rite I, Herrera AJ, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 2004; 16: 190-201.
27. Jantzie L, Todd K,. Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia-ischemia in neonatal rats. J. Psychiatry Neurosci. 2010; 35: 20-32.
28. Webster GF, Toso SM, Hegemann LR,. Inhibition of in vitro granuloma formation by tetracyclines and ciprofloxacin: involvement of protein kinase C. Arch. Dermatol. 1994; 130: 748-752.
29. Lee CZ, Xu B, Hashimoto T, et al. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004; 35: 1715-1719.
30. Garcia-Martinez E, Sanz-Blasco S, Karachitos A, et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochemistry 2010; 79: 239-250.
31. Crawford GH, Pelle MT, James WD,. Rosacea: 1. Etiology, pathogenesis, and subtype classification. J. Am. Acad. Dermatol. 2004; 51: 327-341.
32. Baldwin HE,. Diagnosis and treatment of rosacea: state of the art. J. Drugs Dermatol. 2012; 11: 725-730.
33. Aroni K, Tasgroni E, Lazaris AC, et al. Rosacea: a clinico-pathological approach. Dermatology 2004; 209: 177-182.
34. Dobric I, Basta-Juzbasic A, Skerlev M,. The effectiveness of tetracycline in the treatment of rosacea associated with epithelioid granulomas. Acta Med. Yugosl. 1989; 43: 127-136.
35. Kari M, Kari O, Saari M, et al. Tear fluid levels of MMP-8 are elevated in ocular rosacea-treatment effect of oral doxycycline. Graefes Arch. Clin. Exp. Ophthalmol. 2006; 244: 957-962.
36. Bakar O, Demircay Z, Yuksel M, et al. The effect of azithromycin on reactive oxygen species in rosacea. Clin. Exp. Dermatol. 2007; 32: 197-200.
37. Martinon F,. Signaling by ROS drives inflammasome activation. Eur. J. Immunol. 2010; 40: 616-619.
38. Krauss RL, Pasieczny R, Lariosa-Willingham K, et al. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem. 2005; 94: 819-827.
39. Smith JR, Lanier VB, Braziel RM, et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br. J. Ophthalmol. 2007; 91: 226-229.
40. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailablity and vascular patterning in tumors. J. Cell Biol. 2005; 169: 681-691.
41. Korting HC, Schollman C,. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol. Physiol. 2009; 22: 287-294.
42. Mariotto S, Suzuki Y, Persichini T,. Cross-talk between NO and arachidonic acid in inflammation. Curr. Med. Chem. 2007; 14: 1940-1944.
43. McKeage K, Deaks ED,. Doxycycline 40mg capsules (30mg immediate-release/10mg delayed-release beads): anti-inflammatory dose in rosacea. Am. J. Clin. Dermatol. 2010; 11: 217-222.
44. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J. Am. Acad. Dermatol. 2007; 56: 791-802.
45. Fowler Jr JF,. Combined effect of anti-inflammatory dose doxycycline (40mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J. Drugs Dermatol. 2007; 6: 641-645.
46. Del Rosso JQ, Schlessinger J, Werschler P,. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100mg in the treatment of rosacea. J. Drugs Dermatol. 2008; 7: 573-576.
47. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J. Am. Acad. Dermatol. 2009; 60: S1-50.
48. Lee WL, Shalita AR, Suntharalingam K, et al. Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition. Infect. Immun. 1982; 35: 71-78.
49. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline and erythromycin. Antimicrob. Agents Chemother. 1982; 21: 770-772.
50. Sarici G, Cinar S, Armutcu F, et al. Oxidative stress in acne vulgaris. J. Eur. Acad. Dermatol. Venereol. 2010; 24: 763-767.
51. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch. Dermatol. 2003; 139: 459-464.
52. Toossi P, Farshchian M, Malekzad F, et al. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J. Drugs Dermatol. 2008; 7: 1149-1152.
53. Leyden JJ, Del Rosso JQ, Webster GF,. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007; 79: 9-25.
54. Joshi RK, Atukorala DN, Abanmi A, et al. Successful treatment of Sweet's syndrome with doxycycline. Br. J. Dermatol. 1993; 128: 584-586.
55. Berth-Jones J, Tan SV, Graham-Brown RAC, et al. The successful use of minocycline in pyoderma gangrenosum-a report of seven cases and review of the literature. J. Dermatol. Treatment 1989; 1: 23-25.
56. Khan Durani B, Jappe U,. Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature. Br. J. Dermatol. 2002; 147: 558-6.
57. Miyakazi E, Ando M, Fukami T, et al. Minocycline for the treatment of sarcoidosis: is the mechanism of action immunomodulating or antimicrobial effect? Clin. Rheumatol. 2008; 27: 1195-1197.
58. Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch. Dermatol. 2001; 137: 69-73.
59. Schmitt CE, Fabi SG, Kukreja T, et al. Hypopigmented cutaneous sarcoidosis responsive to minocycline. J. Drugs Dermatol. 2012; 11: 385-389.
60. Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol. 2006; 24: 1389-1394.
61. Sapadin AN, Fleischmajer R,. Tetracyclines: nonacitbiotic properties and their clinical implications. J. Am. Acad. Dermatol. 2006; 54: 258-265.